ÂÜÀòÂÒÂ×

Kevin Anderson is an accomplished professional in the field of clinical operations, currently serving as the Sr. Director of Clinical Operations at Moderna, where Kevin leads a team overseeing early phase rare, autoimmune, and First in Human programs. Previous roles include Sr. Director at AlloVir, where Kevin managed multiple Phase 3 and Phase 2 studies related to viruses associated with stem cell and kidney transplants. At PTC Therapeutics, Inc., Kevin oversaw Phase 3 studies for various rare diseases and played a key role in establishing a new Phase 1 group. During tenure at Alexion Pharmaceuticals, Kevin served as the Director of Global Clinical Operations, managing a diverse portfolio of rare disease programs and successfully contributing to regulatory submissions. Kevin's earlier experiences include managerial positions at Shire, CR Bard, Biogen, and Amgen, showcasing a consistent track record of leadership across various therapeutic areas. Kevin holds an MBA from Boston College Carroll School of Management and a BA in Psychology from Eastern University.